Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...

The US Preventive Services Task Force recently issued a recommendation statement for preexposure prophylaxis (PrEP) for HIV, but it is so broadly worded that it will be subject to vast payer ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Forty-year-old Thulisile Nkosi* carefully counts the pills in her bottle before handing over a few to her friend.

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...